Eli Lilly, Boehringer Ingelheim Get FDA OK for Jardiance in Chronic Kidney Disease

Is Eli Lilly Stock A Buy Now That It Has Topped A Profit-Taking Zone?

Medtech Makers Are Real Losers From Obesity Drugs

How Ozempic and Wegovy Could Break the Healthcare System

Is Eli Lilly Stock A Buy Now That It Has Topped A Profit-Taking Zone?

Is Eli Lilly Stock A Buy Now That It Has Hit A Profit-Taking Zone?

How Stocks Pass Quality Test Of This Best Mutual Fund

Weight-Loss Drug Market Can Hit $100 Billion, J.P. Morgan Says. Eli Lilly Is a Big Winner.

Novo Nordisk Is Europe’s Biggest Company. Wegovy Helps.

To Pay for Weight Loss Drugs, Some Take Second Jobs, Ring Up Credit-Card Debts

8 Stocks Turn $10,000 Into $125,279 In 8 Months

Eli Lilly Has A Big Stake In Weight Loss And Alzheimer's Drugs; But Is The Stock A Buy?

Global Dividends Hit a Record High, Driven by Banks

Expensive Drugs Targeted for First U.S. Price Negotiations

The Unexpected Bad News For Novo's Ozempic In Biden's Drug Negotiations List

First 10 Drugs Picked for Medicare Price Negotiations

Eliquis, Jardiance among first 10 drugs selected for Medicare price negotiations

Warren Buffett Bets His Fortune On One Of 9 'Can't Lose' Stocks

Biden Administration to Reveal 10 Drugs for Which Medicare Will Pay Less

How Novo Nordisk, A Top 1% Stock, Just Hit Another Bull's-eye In Obesity Treatment